<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082329</url>
  </required_header>
  <id_info>
    <org_study_id>040179</org_study_id>
    <secondary_id>04-H-0179</secondary_id>
    <nct_id>NCT00082329</nct_id>
  </id_info>
  <brief_title>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</brief_title>
  <official_title>Peripheral Blood Hematopoietic Progenitor Cell Mobilization Using Granulocyte Colony Stimulating Factor (G-CSF) Combined With AMD3100 Mozobil (Plerixafor) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating&#xD;
      factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than&#xD;
      the use of G-CSF alone. Traditionally, the growth factor G-CSF has been given to stem cell&#xD;
      donors to mobilize, or push, stem cells out of the bone marrow and into the blood circulation&#xD;
      for collection for transplantation. Although a sufficient quantity of cells usually can be&#xD;
      collected with G-CSF treatment, some donors do not respond well and may require multiple&#xD;
      apheresis procedures (see below) to collect enough cells. Studies indicate that G-CSF used&#xD;
      together with a drug called AMD3100 may be more effective in mobilizing stem cells for&#xD;
      collection than G-CSF alone. The Food and Drug Administration has approved G-CSF for stem&#xD;
      cell mobilization. AMD3100 is a new drug that also mobilizes stem cells in large numbers&#xD;
      within a few hours.&#xD;
&#xD;
      Normal healthy volunteers between 18 and 60 years of age may be eligible for this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral blood progenitor cells (PBPC) are the most popular source of hematopoetic stem&#xD;
      cells for allogeneic transplantation because of technical ease of collection and faster&#xD;
      engraftment. Traditionally, granulocyte-colony stimulating factor (G-CSF) has been used to&#xD;
      procure the peripheral blood stem cell graft. Although regimens using G-CSF usually succeed&#xD;
      in collecting adequate numbers of PBPC from healthy donors, 5%-10% of the donors will&#xD;
      mobilize stem cells poorly and may require multiple large volume apheresis or bone marrow&#xD;
      harvesting. AMD3100 reversibly inhibits CXC- chemokine receptor 4 (CXCR4) binding to stromal&#xD;
      cell derived factor (SDF) - 1 and was recently discovered to be an effective agent to&#xD;
      mobilize cluster of differentiation 34 (CD34)+ cells into the peripheral blood. In normal&#xD;
      volunteers, administering AMD3100 after 4-5 days of G-CSF resulted in a 3-3.5 fold increase&#xD;
      in circulating CD34 cells compared to G-CSF alone. Recent data has suggested that the&#xD;
      combination of G-CSF and AMD3100 is superior to G-CSF alone for mobilizing hematopoietic&#xD;
      progenitor cells in heavily pretreated patients with multiple myeloma or non-Hodgkin's&#xD;
      lymphoma undergoing autologous hematopoietic transplantation. Combining AMD3100 with G-CSF&#xD;
      could be an effective strategy to improve the yield of PBPC collected from allogeneic donors&#xD;
      who mobilize poorly with G-CSF alone. However, the biological impact of AMD3100 in this&#xD;
      context on T cells and other cellular populations contained within the allograft that mediate&#xD;
      graft versus host disease (GVHD) and graft-versus-leukemia (GVL) effects are unknown.&#xD;
&#xD;
      We propose to collect peripheral progenitor cell (PBPC) from healthy volunteers following 5&#xD;
      days of G-CSF (10 mcg/kg/day) and a single dose of AMD3100 (240 mcg/kg subcutaneous given 12&#xD;
      hours before starting apheresis) to study the impact of combining these two mobilizing agents&#xD;
      on the immunological properties of the mobilized cells. A single 15 liter apheresis will be&#xD;
      conducted on day 5 following the 5th dose of G-CSF. The immunological studies conducted on&#xD;
      these mobilized cells will be the same as our parallel study which is investigating the&#xD;
      immune properties of PBPCs mobilized with G-CSF or AMD3100 alone. If combining AMD3100 with&#xD;
      G-CSF has no negative impact on the immune populations involved in GVHD and graft-vs-leukemia&#xD;
      effects, this regimen could be used for allogeneic donors who fail to mobilize sufficient&#xD;
      peripheral blood stem cell (PBSC) using G-CSF alone.&#xD;
&#xD;
      Primary objective: To determine the cytokine polarization status of cluster of&#xD;
      differentiation 4 (CD4+) T-cells collected by apheresis following combination of AMD3100 and&#xD;
      G-CSF compared to G-CSF mobilization.&#xD;
&#xD;
      Primary endpoint: the ratio of Th1 [intracellular interferon (IFN-g) +] versus Th2&#xD;
      [intracellular interleukin (IL-4+)] T-cells in the apheresis products collected from&#xD;
      individual donors undergoing mobilization with combination of G-CSF and AMD3100 to the ratio&#xD;
      in apheresis product collected with G-CSF alone (ratio published in literature).&#xD;
&#xD;
      Secondary endpoints: To examine 1) the cellular content and other immune properties of&#xD;
      mobilized cells; 2) yields of hematopoietic progenitor cells, immune cells, and other&#xD;
      cellular subsets collected by apheresis; and the 3) safety profile of AMD3100.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2004</start_date>
  <completion_date type="Actual">October 25, 2012</completion_date>
  <primary_completion_date type="Actual">October 25, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Successful Apheresis Collection Following Combination of AMD3100 and G-CSF.</measure>
    <time_frame>Day 1 (cells are counted 24 hours after AMD3100)</time_frame>
    <description>Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis.&#xD;
We propose that the combination of single dose AMD 3100 and G-CSF as combined mobilizing agents will improve the peripheral blood progenitor cells mobilization. Successful treatment responders is defined by completing study treatment with cell mobilization and cell collection. Non-responders is defined by having completed the study treatment and having cell mobilization without cell collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Fold Change From Baseline of Mobilized Cells Following G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</measure>
    <time_frame>Day 7</time_frame>
    <description>Average fold change from baseline of mobilized cells that contained immune properties and other cellular content following G-CSF and AMD3100 to mobilize stem cells in healthy volunteers. The mobilized cells are defined as: white blood cells, lymphocytes, polys and monocytes. Polys (also known as segs, segmented neutrophils, neutrophils, granulocytes) are the most numerous of our white blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increased the Levels of Circulating Hematopoietic Progenitor Cells, Immune Cells, and Other Cellular Subsets Collected by Apheresis.</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of participants with increase in yields of hematopoietic progenitor cells, immune cells, and other cellular subsets collected by apheresis following G-CSF and AMD3100 to mobilize stem cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received subcutaneous injection of G-CSF (10 mcg/kg/day) for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMD 3100 (Mozobil plerixafor)</intervention_name>
    <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.</description>
    <arm_group_label>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</arm_group_label>
    <other_name>AMD 3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte colony-stimulating factor (G-CSF)</intervention_name>
    <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.</description>
    <arm_group_label>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Healthy volunteers greater or equal to 18 years old, less than or equal to 60 years.&#xD;
&#xD;
        Weight greater than 60 kg (132 pounds)&#xD;
&#xD;
        Normal renal function: creatinine less than 1.5 mg/dl l&#xD;
&#xD;
        Normal liver function: bilirubin less than1.5mg/dl, transaminases within normal limit&#xD;
&#xD;
        Normal blood count: white blood cell (WBC) 3000-10000/mm3, granulocytes greater than&#xD;
        1500/mm3, platelets greater than 150,000/mm3, hemoglobin greater than 12.5g/dl&#xD;
&#xD;
        Subject must be eligible for normal blood donation and fit to undergo apheresis procedure&#xD;
        (antecubital veins must be adequate for peripheral access during apheresis)&#xD;
&#xD;
        Ability to comprehend the investigational nature of the study and provide informed consent&#xD;
&#xD;
        EXCLUSION CRITERIA: any of the following&#xD;
&#xD;
        Active infection or history of recurrent infection or positive test for syphilis (RPR),&#xD;
        hepatitis B and C (HBaSAg, Anti-HCV), HIV and human T- Lymphocytic virus (HTLV-1)&#xD;
&#xD;
        History of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematous&#xD;
&#xD;
        History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma&#xD;
        of the skin&#xD;
&#xD;
        History of any hematologic disorders including thromboembolic disease&#xD;
&#xD;
        History of cardiac disease such as uncontrolled hypertension, peripheral vascular disease,&#xD;
        myocardial infarction, cardiac arrhythmias or related symptoms such as tachycardia, chest&#xD;
        pain, shortness of breath which have required medical intervention or treatment or a&#xD;
        Framingham coronary disease risk prediction score of greater than 10% 10 year coronary&#xD;
        heart disease (CHD) risk&#xD;
&#xD;
        History of heavy smoking with underlying pulmonary disease&#xD;
&#xD;
        History of cerebrovascular disease, transient ischemic attack, or stroke&#xD;
&#xD;
        Diagnosis of sickle cell anemia or sickle cell trait (to be screened by hemoglobin (Hbg)&#xD;
        electrophoresis)&#xD;
&#xD;
        Pregnant or lactating&#xD;
&#xD;
        Severe psychiatric illness: mental deficiency sufficiently severe as to make informed&#xD;
        consent impossible.&#xD;
&#xD;
        Mobilization with G-CSF within 90 days of protocol enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard W Childs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2004-H-0179.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant. 2000 Jul;26(1):1-16. Review.</citation>
    <PMID>10918400</PMID>
  </reference>
  <reference>
    <citation>Bellucci R, De Propris MS, Buccisano F, Lisci A, Leone G, Tabilio A, de Fabritiis P. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant. 1999 Jan;23(1):1-8.</citation>
    <PMID>10037043</PMID>
  </reference>
  <reference>
    <citation>MÃ¶hle R, Murea S, Kirsch M, Haas R. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol. 1995 Dec;23(14):1535-42.</citation>
    <PMID>8542944</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2004</study_first_submitted>
  <study_first_submitted_qc>May 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2004</study_first_posted>
  <results_first_submitted>April 1, 2014</results_first_submitted>
  <results_first_submitted_qc>April 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2014</results_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Stem Cells</keyword>
  <keyword>PBSC's</keyword>
  <keyword>Mobilization</keyword>
  <keyword>Alloreactivity</keyword>
  <keyword>T Cell Polarization</keyword>
  <keyword>Dendritic Cells</keyword>
  <keyword>CXCR4</keyword>
  <keyword>Plerixafor</keyword>
  <keyword>Healthy Volunteer (HV)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
          <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection was performed on the fifth day following G-CSF administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
          <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection was performed on the fifth day following G-CSF administration.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Apheresis Collection Following Combination of AMD3100 and G-CSF.</title>
        <description>Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis.&#xD;
We propose that the combination of single dose AMD 3100 and G-CSF as combined mobilizing agents will improve the peripheral blood progenitor cells mobilization. Successful treatment responders is defined by completing study treatment with cell mobilization and cell collection. Non-responders is defined by having completed the study treatment and having cell mobilization without cell collection.</description>
        <time_frame>Day 1 (cells are counted 24 hours after AMD3100)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
            <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection was performed on the fifth day following G-CSF administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Apheresis Collection Following Combination of AMD3100 and G-CSF.</title>
          <description>Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis.&#xD;
We propose that the combination of single dose AMD 3100 and G-CSF as combined mobilizing agents will improve the peripheral blood progenitor cells mobilization. Successful treatment responders is defined by completing study treatment with cell mobilization and cell collection. Non-responders is defined by having completed the study treatment and having cell mobilization without cell collection.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AMD &amp; G-CSF Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AMD&amp; G-CSF Non-Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Fold Change From Baseline of Mobilized Cells Following G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
        <description>Average fold change from baseline of mobilized cells that contained immune properties and other cellular content following G-CSF and AMD3100 to mobilize stem cells in healthy volunteers. The mobilized cells are defined as: white blood cells, lymphocytes, polys and monocytes. Polys (also known as segs, segmented neutrophils, neutrophils, granulocytes) are the most numerous of our white blood cells.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
            <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection was performed on the fifth day following G-CSF administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Fold Change From Baseline of Mobilized Cells Following G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
          <description>Average fold change from baseline of mobilized cells that contained immune properties and other cellular content following G-CSF and AMD3100 to mobilize stem cells in healthy volunteers. The mobilized cells are defined as: white blood cells, lymphocytes, polys and monocytes. Polys (also known as segs, segmented neutrophils, neutrophils, granulocytes) are the most numerous of our white blood cells.</description>
          <units>Mean Fold Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White Blood Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="6.6" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.4" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="7.2" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="2.2" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increased the Levels of Circulating Hematopoietic Progenitor Cells, Immune Cells, and Other Cellular Subsets Collected by Apheresis.</title>
        <description>Number of participants with increase in yields of hematopoietic progenitor cells, immune cells, and other cellular subsets collected by apheresis following G-CSF and AMD3100 to mobilize stem cells.</description>
        <time_frame>Day 7</time_frame>
        <population>1 participant did not complete apheresis, therefore 1 participant was not included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
            <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection was performed on the fifth day following G-CSF administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increased the Levels of Circulating Hematopoietic Progenitor Cells, Immune Cells, and Other Cellular Subsets Collected by Apheresis.</title>
          <description>Number of participants with increase in yields of hematopoietic progenitor cells, immune cells, and other cellular subsets collected by apheresis following G-CSF and AMD3100 to mobilize stem cells.</description>
          <population>1 participant did not complete apheresis, therefore 1 participant was not included in analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers</title>
          <description>Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection was performed on the fifth day following G-CSF administration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alk Phos</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Elevated LDH</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Elevated WBCs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>achy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Appetite decr'd</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Body ache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>low back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tiredness (fatigue)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>low back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>paresthia (facial tingling)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising, local at IV site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Childs</name_or_title>
      <organization>NHLBI NIH</organization>
      <phone>301-594-8008</phone>
      <email>childsr@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

